Horizon Therapeutics Plc (HZNP)

22.81
NASDAQ : Health Technology
Prev Close 23.60
Day Low/High 22.77 / 23.68
52 Wk Low/High 15.92 / 29.44
Avg Volume 1.46M
Exchange NASDAQ
Shares Outstanding 184.88M
Market Cap 4.36B
EPS -0.50
P/E Ratio 90.77
Div & Yield N.A. (N.A)

Latest News

Horizon Therapeutics Plc To Participate In The JMP Securities Life Sciences Conference

Horizon Therapeutics Plc To Participate In The JMP Securities Life Sciences Conference

Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the company will participate in the following conference in June: The JMP Securities Life Sciences Conference Date: June 20, 2019 Presentation Time: 10 a.

Horizon Therapeutics Plc And Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program

Horizon Therapeutics Plc And Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program

Horizon Therapeutics plc (Nasdaq: HZNP) in partnership with Invitae Corporation (NYSE: NVTA) today announced a new urea cycle disorder (UCD) genetic testing program designed to speed diagnosis and enable physicians to offer genetic testing at no-charge to...

Horizon Named One Of The Best Workplaces In Chicago By Great Place To Work® And FORTUNE

Horizon Named One Of The Best Workplaces In Chicago By Great Place To Work® And FORTUNE

Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been selected to the FORTUNE and Great Place to Work® 2019 " Best Workplaces in Chicago" list.

Horizon Therapeutics Plc Launches New Data-Driven Campaign To Reset The Dialogue On Gout

Horizon Therapeutics Plc Launches New Data-Driven Campaign To Reset The Dialogue On Gout

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of Gout Lies , a data-driven campaign to reframe physician dialogue on the reality of living with gout and underscore findings of recent research that warrant a new view on how to properly...

Horizon Therapeutics Plc Announces Tina Ventura As A Healthcare Businesswomen's Association 2019 Luminary

Horizon Therapeutics Plc Announces Tina Ventura As A Healthcare Businesswomen's Association 2019 Luminary

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that Tina Ventura, senior vice president, investor relations, has been named a 2019 Healthcare Businesswomen's Association (HBA) Luminary.

Horizon Therapeutics Plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales And Adjusted EBITDA Guidance

Horizon Therapeutics Plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales And Adjusted EBITDA Guidance

Horizon Therapeutics plc (Nasdaq: HZNP) today announced its first-quarter 2019 financial results and increased its full-year 2019 net sales and adjusted EBITDA guidance.

Horizon Therapeutics Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Therapeutics Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2019 of inducement restricted stock units for an aggregate of 53,008 ordinary shares to 31 new employees.

New Data From Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction In Proptosis, Or Eye Bulging, The Main Cause Of Morbidity In Active Thyroid Eye Disease (TED)

New Data From Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction In Proptosis, Or Eye Bulging, The Main Cause Of Morbidity In Active Thyroid Eye Disease (TED)

Horizon Pharma plc (Nasdaq: HZNP) today announced that new data from the Phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED) were presented as part of a...

Horizon Pharma Plc And Gift Of Adoption Announce A New Fund To Facilitate Global Adoptions Of Children With Rare Diseases

Horizon Pharma Plc And Gift Of Adoption Announce A New Fund To Facilitate Global Adoptions Of Children With Rare Diseases

Horizon Pharma plc (Nasdaq: HZNP) in partnership with Gift of Adoption today announced the creation of the #RAREis Adoption Fund to help facilitate global adoptions of children with rare diseases.

Horizon Pharma Plc To Present Results From Its Phase 3 Teprotumumab Trial (OPTIC) at The 2019 American Association Of Clinical Endocrinologists (AACE) Scientific And Clinical Congress

Horizon Pharma Plc To Present Results From Its Phase 3 Teprotumumab Trial (OPTIC) at The 2019 American Association Of Clinical Endocrinologists (AACE) Scientific And Clinical Congress

Horizon Pharma plc (Nasdaq: HZNP) today announced that it will present additional results from its Phase 3 confirmatory clinical trial (OPTIC) evaluating teprotumumab for the treatment of active thyroid eye disease (TED) at the 2019 American Association...

Horizon Pharma Plc Named One Of The 2019 Best Workplaces In Health Care And Biopharma By FORTUNE And Great Place To Work®

Horizon Pharma Plc Named One Of The 2019 Best Workplaces In Health Care And Biopharma By FORTUNE And Great Place To Work®

Horizon Pharma plc (NASDAQ:HZNP) today announced it has been selected as one of the 2019 Best Workplaces in Health Care and Biopharma by Great Place to Work® and  FORTUNE Magazine.

Horizon Pharma Plc To Release First-Quarter 2019 Financial Results And Host Webcast On May 8, 2019

Horizon Pharma Plc To Release First-Quarter 2019 Financial Results And Host Webcast On May 8, 2019

Horizon Pharma plc (Nasdaq: HZNP) announced today that its first-quarter 2019 financial results will be released on Wednesday, May 8, 2019.

Horizon Pharma Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Pharma Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Pharma plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on April 1, 2019 of inducement restricted stock units for an aggregate of 48,477 ordinary shares to 14 new employees.

Horizon Pharma Plc Wins PR News CSR Award For Partnership With Perspectives Math And Science Academy

Horizon Pharma Plc Wins PR News CSR Award For Partnership With Perspectives Math And Science Academy

Horizon Pharma plc (Nasdaq: HZNP) announced today that it has won a PR News CSR Award in the Corporation category for its impactful partnership with Chicago-based charter school, Perspectives Math and Science Academy (MSA).

Horizon Pharma Plc Announces Closing Of Public Offering Of Ordinary Shares And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Horizon Pharma Plc Announces Closing Of Public Offering Of Ordinary Shares And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Horizon Pharma plc (Nasdaq: HZNP) today announced the closing of its underwritten public offering of 14,081,632 of its ordinary shares at a price to the public of $24.

Horizon Pharma Plc Announces Pricing Of Public Offering Of Ordinary Shares

Horizon Pharma Plc Announces Pricing Of Public Offering Of Ordinary Shares

Horizon Pharma plc (Nasdaq: HZNP) today announced the pricing of its underwritten public offering of 12,244,898 of its ordinary shares at a price to the public of $24.

Horizon Pharma Plc Announces Proposed Public Offering Of Ordinary Shares

Horizon Pharma Plc Announces Proposed Public Offering Of Ordinary Shares

Horizon Pharma plc (Nasdaq: HZNP) today announced that it is offering to sell $300,000,000 of its ordinary shares in an underwritten public offering.

Celebrating the Greatness of Individual Traders

Celebrating the Greatness of Individual Traders

Good individual traders will produce returns far in excess of anything that traditional Wall Street will earn.

Horizon Pharma Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Pharma Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Pharma plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on March 1, 2018 of inducement restricted stock units for an aggregate of 8,544 ordinary shares to six new employees.

Noteworthy Thursday Option Activity: HZNP, WSM, HABT

Noteworthy Thursday Option Activity: HZNP, WSM, HABT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Horizon Pharma plc , where a total of 17,761 contracts have traded so far, representing approximately 1.8 million underlying shares. That amounts to about 104.2% of HZNP's average daily trading volume over the past month of 1.7 million shares.

Horizon Pharma Stock Goes Vertical After Positive Eye Disease Drug Results

Horizon Pharma Stock Goes Vertical After Positive Eye Disease Drug Results

Horizon Pharma's stock price skyrockets after the Dublin-based biotech reports positive results for a new drug to treat a rare but devastating eye disease.

Horizon Pharma Plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) For The Treatment Of Active Thyroid Eye Disease (TED) Met Primary And All Secondary Endpoints

Horizon Pharma Plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) For The Treatment Of Active Thyroid Eye Disease (TED) Met Primary And All Secondary Endpoints

Horizon Pharma plc (Nasdaq: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED).

Horizon Pharma Plc Reports Record Fourth-Quarter And Full-Year 2018 Net Sales Driven By Orphan And Rheumatology Segment; Announces Full-Year 2019 Guidance

Horizon Pharma Plc Reports Record Fourth-Quarter And Full-Year 2018 Net Sales Driven By Orphan And Rheumatology Segment; Announces Full-Year 2019 Guidance

Horizon Pharma plc (Nasdaq: HZNP) today announced its fourth-quarter and full-year 2018 financial results and provided its full-year 2019 net sales and adjusted EBITDA guidance.

Horizon Pharma Plc To Participate In Cowen And Company 39th Annual Health Care Conference

Horizon Pharma Plc To Participate In Cowen And Company 39th Annual Health Care Conference

Horizon Pharma plc (Nasdaq: HZNP), today announced that the company will participate in the following conference in March: Cowen and Company 39 th Annual Health Care Conference Date: March 11, 2019 Presentation Time: 12 p.

PepsiCo, Ford Motor, Teladoc: 'Mad Money' Lightning Round

PepsiCo, Ford Motor, Teladoc: 'Mad Money' Lightning Round

Jim Cramer weighs in on PepsiCo, Ford Motor, Teladoc, First Majestic Silver, Horizon Pharmaceuticals, Campbell Soup.

The Value of Patience: Cramer's 'Mad Money' Recap (Wednesday 1/30/19)

The Value of Patience: Cramer's 'Mad Money' Recap (Wednesday 1/30/19)

The Fed opted to exercise patience and see what happens with the economy -- and both the American people and the financial markets benefit.

Horizon Pharma Plc To Release Fourth-Quarter And Full-Year 2018 Financial Results And Host Webcast On Feb. 27, 2019

Horizon Pharma Plc To Release Fourth-Quarter And Full-Year 2018 Financial Results And Host Webcast On Feb. 27, 2019

Horizon Pharma plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2018 financial results will be released on Wednesday, Feb.

Horizon Pharma Plc And HemoShear Therapeutics Enter Into Exclusive Drug Discovery Collaboration In Gout

Horizon Pharma Plc And HemoShear Therapeutics Enter Into Exclusive Drug Discovery Collaboration In Gout

Horizon Pharma plc (Nasdaq: HZNP) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a collaboration to discover and develop novel therapeutics for gout.

TheStreet Quant Rating: C+ (Hold)